Good
Mostly Aligned
Patient Risk:
Low
Summary
Most drug-use, mechanism, administration, contraindication, and common adverse-effect statements match the label content provided. Several claims are either more general than supported (e.g., side effects dose-dependency timing phrasing) or partially unsupported (e.g., combination use specifics for memantine, generic availability/patent statements).
Category Scores
Accurate Statements
Donepezil belongs to the drug class of acetylcholinesterase inhibitors.
12.1 Mechanism of Action; description of reversible inhibition of acetylcholinesterase; elsewhere implies class of cholinesterase inhibitors.
Donepezil inhibits the enzyme acetylcholinesterase.
11 DESCRIPTION; 12.1 Mechanism of Action.
Acetylcholinesterase is responsible for breaking down acetylcholine.
12.1 Mechanism of Action: reversible inhibition of hydrolysis by acetylcholinesterase.
By blocking acetylcholinesterase, donepezil allows more acetylcholine to be available in the synaptic cleft.
12.1 Mechanism of Action: increases concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase.
Donepezil enhances cholinergic neurotransmission.
12.1 Mechanism of Action: enhancing cholinergic function.
Increased cholinergic neurotransmission is thought to improve cognitive function in individuals with Alzheimer's disease.
12.1 Mechanism of Action describes deficiency of cholinergic neurotransmission and therapeutic effect by enhancing cholinergic function.
Acetylcholinesterase inhibitors are primarily used to manage the cognitive symptoms of Alzheimer's disease.
1 INDICATIONS AND USAGE: treatment of dementia of the Alzheimer’s type; 12.1 Mechanism of Action discusses cognitive signs/symptoms.
Donepezil is usually taken orally.
11 DESCRIPTION: available for oral administration in film-coated tablets.
Donepezil is usually taken once a day.
2 DOSAGE AND ADMINISTRATION; 17 Patient Counseling Information: take tablets only once per day.
Donepezil is typically taken at bedtime.
2 DOSAGE AND ADMINISTRATION: in the evening, just prior to retiring.
Common starting dose of donepezil is 5 mg.
2.1 and 2.2: recommended starting dosage is 5 mg once per day in evening.
Donepezil may be increased to 10 mg as tolerated.
2.1: maximum 10 mg/day in mild to moderate; dose of 10 mg should not be administered until patients have been on 5 mg for 4 to 6 weeks (tolerability concept is supported by 'as tolerated' elsewhere, and label uses time-gated step-up).
Common side effects of donepezil can include nausea.
17 Patient Counseling Information: may cause nausea.
Common side effects of donepezil can include vomiting.
6 ADVERSE REACTIONS lists 'Nausea and Vomiting'; 17 Patient Counseling Information: may cause vomiting.
Common side effects of donepezil can include diarrhea.
17 Patient Counseling Information: may cause diarrhea.
Common side effects of donepezil can include loss of appetite.
17 Patient Counseling Information: may cause decreased appetite.
Common side effects of donepezil can include fatigue.
17 Patient Counseling Information: may cause fatigue.
Common side effects of donepezil can include insomnia.
17 Patient Counseling Information: may cause insomnia.
Common side effects of donepezil can include muscle cramps.
17 Patient Counseling Information: may cause muscle cramps.
Donepezil can cause serious side effects such as bradycardia (slow heart rate).
5.2 Cardiovascular Conditions: may manifest as bradycardia or heart block.
Donepezil can cause serious side effects such as fainting.
5.2 Cardiovascular Conditions: Syncopal episodes have been reported.
Donepezil can cause serious side effects such as stomach ulcers.
5.4 Peptic Ulcer Disease and GI Bleeding: monitor for symptoms; label discusses peptic ulcer disease.
Donepezil can cause serious side effects such as breathing problems.
5.8 Pulmonary Conditions: cholinesterase inhibitors should be prescribed with care in asthma/obstructive pulmonary disease; 6 lists 'Pulmonary Conditions' as serious adverse reactions described elsewhere.
Donepezil serious side effects can be more likely in individuals with pre-existing heart conditions.
5.2 Cardiovascular Conditions: bradycardia or heart block in patients both with and without known underlying cardiac conduction abnormalities (supports that there is relevance to underlying cardiac conduction abnormalities).
Donepezil is contraindicated in patients with known hypersensitivity to donepezil hydrochloride or to piperidine derivatives.
4 CONTRAINDICATIONS.
Unsupported Statements
Rivastigmine and galantamine are acetylcholinesterase inhibitor drugs.
The provided label text does not mention rivastigmine or galantamine.
Rivastigmine and galantamine share a similar mechanism of action with donepezil.
No rivastigmine/galantamine mechanism statements are present in the provided label excerpts.
Rivastigmine and galantamine may differ in their pharmacokinetics.
Not addressed in the provided label excerpts.
Rivastigmine and galantamine may differ in their side effect profiles.
Not addressed in the provided label excerpts.
Side effects of donepezil are often dose-dependent.
Label provided does not state general dose-dependency of side effects; only specific GI bleeding/ulcer incidence differences by 23 mg vs 10 mg are described.
Side effects may be more pronounced when starting donepezil.
No timing of side-effect onset relative to initiation is stated in the provided label excerpts.
Side effects may be more pronounced when increasing the dose of donepezil.
Label provides limited evidence regarding peptic ulcer disease/GI bleeding incidence at higher dose (23 mg vs 10 mg), but the broad claim about side effects in general is not directly supported.
Donepezil serious side effects can be more likely in individuals taking other medications that affect heart rate.
The provided label excerpt does not identify drug classes that 'affect heart rate' as increasing serious adverse-event likelihood.
Generic versions of donepezil are available.
No regulatory/market availability or patent-expiration statements are present in the provided label text.
Once patents expire, other pharmaceutical companies can manufacture and market generic versions of donepezil.
Not addressed in the provided label.
Generic versions of donepezil are typically less expensive than the brand-name product.
Not addressed in the provided label.
Memantine is an NMDA receptor antagonist.
Not addressed in the provided label.
Donepezil and memantine work through different mechanisms to treat Alzheimer's disease.
Memantine is not addressed in the provided label excerpts; only donepezil mechanism is provided.
Memantine modulates glutamate activity.
Not addressed in the provided label.
Donepezil and memantine are sometimes used in combination for moderate to severe Alzheimer's disease.
Not addressed in the provided label excerpts.
Contradictions
Important Omissions
For dose escalation, the label specifies timing constraints (e.g., 10 mg not until 4 to 6 weeks on 5 mg; in moderate-to-severe, 23 mg not until patients have been on 10 mg for at least 3 months) and a maximum dose by disease severity.
Importance:
Moderate
The label includes additional counseling points (e.g., 'can be taken with or without food') and pregnancy/lactation and pediatric safety statements that were not mentioned by the AI statements.
Importance:
Moderate
Dose-specific GI bleeding/ulcer findings: increased incidence at 23 mg/day vs 10 mg/day is described.
Importance:
Moderate
Drug interaction counseling: synergistic effect expected when cholinesterase inhibitors are given concurrently with succinylcholine/similar neuromuscular blockers or cholinergic agonists (e.g., bethanechol).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most mechanistic, administration, contraindication, and labeled serious adverse effects are consistent with the provided label. However, broad dose-dependency/timing assertions and unsupported combination/market-availability claims could mislead, but do not directly provide a dosing instruction that contradicts label content.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several statements are not supported by the provided label excerpts (other AChE inhibitors comparison, memantine details, generic availability) and some safety assertions are overly general (dose-dependency and timing of side effects).
Suggested Improvement
Restrict claims to those explicitly supported by the provided label sections: include label-specific dose-escalation timing and maximum doses by severity; avoid unlabelled comparisons (rivastigmine/galantamine) and memantine combination assertions unless present in the label; narrow side-effect timing/dose-dependency claims to the specific labeled findings (e.g., 23 mg vs 10 mg GI bleeding/ulcer incidence).